Progress of researches on biological therapies targeting type 2 inflammation and risk of parasitic infections

doi:10.12140/j.issn.1000-7423.2026.01.019

Abstract

Abstract:

Recently, biologics targeting type 2 inflammatory pathways, such as interleukin-4 (IL-4)/IL-13, IL-5, and immunoglobulin E (IgE), have become effective approaches for treatment of type 2 inflammatory diseases. Nevertheless, these biologics not only precisely suppress excessive inflammatory responses, but also interfere with the body’s capability to fight against parasitic infections, thereby increasing the risk of infection. Although such adverse events are relatively rare, their potential associations have been paid attention in clinical practices. Currently, there is still a lack of systematic understanding regarding the exact mechanisms underlying parasitic infections induced by biologics with diverse targets, the characteristics of high-risk populations, and clinical management strategies. This article aims to provide a review of these aspects, so as to provide insights into clinical practices.

Key words: Parasitic infection, Antibody, Monoclonal, Immune response, Biological product

CLC Number:

R967

CAI Wenlin, LIU Xu, HU Ke. Progress of researches on biological therapies targeting type 2 inflammation and risk of parasitic infections[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2026, 44(1): 130-136.

Figures/Tables 2

References 46

[1]	李伟, 侯冠华, 邢移楠, 等. 度普利尤单抗在2型炎症性疾病治疗中应用研究进展[J]. 中华实用诊断与治疗杂志, 2025, 39(12): 1057-1062.
	Li W, Hou GH, Xing YN, et al. Research progress on the application of Dupilumab in the treatment of type 2 inflammatory diseases[J]. Chin J Practical Diagn Ther, 2025, 39(12): 1057-1062. (in Chinese)
[2]	Tsou AM, Yano H, Parkhurst CN, et al. Neuropeptide regulation of non-redundant ILC2 responses at barrier surfaces[J]. Nature, 2022, 611(7937): 787-793.
[3]	Petta I, Thorp M, Ciers M, et al. Myeloid A20 is critical for alternative macrophage polarization and type-2 immune-mediated helminth resistance[J]. Front Immunol, 2024, 15: 1373745.
[4]	Ogulur I, Mitamura Y, Yazici D, et al. Type 2 immunity in allergic diseases[J]. Cell Mol Immunol, 2025, 22(3): 211-242.
[5]	Maspero J, Adir Y, Al-Ahmad M, et al. Type 2 inflammation in asthma and other airway diseases[J]. ERJ Open Res, 2022, 8(3): 00576-02021.
[6]	Haddad EB, Cyr SL, ARIMA K, et al. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis[J]. Dermatol Ther, 2022, 12(7): 1501-1533.
[7]	Charles N, Blank U. IgE-mediated activation of mast cells and basophils in health and disease[J]. Immunol Rev, 2025, 331(1): e70024.
[8]	Perez MG, Gillan V, Anderson WM, et al. A secreted helminth microRNA suppresses gastrointestinal cell differentiation required for innate immunity[J]. Front Immunol, 2025, 16: 1558132.
[9]	Zaros LG, Neves MR, Benvenuti CL, et al. Response of resistant and susceptible Brazilian Somalis crossbreed sheep naturally infected by Haemonchus contortus[J]. Parasitol Res, 2014, 113(3): 1155-1161.
[10]	Maizels RM, McSorley HJ, Smits HH, et al. Cytokines from parasites: manipulating host responses by molecular mimicry[J]. Biochem J, 2025, 482(9): 433-449.
[11]	Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma[J]. J Allergy Clin Immunol, 2019, 143(5): 1742-1751.e7.
[12]	Hurdayal R, Nieuwenhuizen NE, Revaz-Breton M, et al. Deletion of IL-4 receptor alpha on dendritic cells renders BALB/c mice hypersusceptible to Leishmania major infection[J]. PLoS Pathog, 2013, 9(10): e1003699.
[13]	Bancroft AJ, McKenzie AN, Grencis RK. A critical role for IL-13 in resistance to intestinal nematode infection[J]. J Immunol, 1998, 160(7): 3453-3461.
[14]	谷美龄, 李亦梅, 郑宏. IFN-γ、IL-4在寄生虫感染免疫中作用的研究进展[J]. 地方病通报, 2010(3): 69-71.
	Gu ML, Li YM, Zheng H. Research progress on the role of IFN-γ and IL-4 in parasite infection immunity[J]. Endem Dis Bull, 2010(3): 69-71. (in Chinese)
[15]	Ramonell RP, Gauthier MC, Ray A, et al. Biologic medications for severe asthma: implications for understanding pathogenic heterogeneity and endotypes[J]. Annu Rev Med, 2025, 76(1): 339-355.
[16]	Jackson JA, Turner JD, Rentoul L, et al. T helper cell type 2 responsiveness predicts future susceptibility to gastrointestinal nematodes in humans[J]. J Infect Dis, 2004, 190(10): 1804-1811.
[17]	Tan LD, Schaeffer B, Alismail A. Parasitic (helminthic) infection while on asthma biologic treatment: not everything is what it seems[J]. J Asthma Allergy, 2019, 12: 415-420.
[18]	Heeb LEM, Boyman O. Comprehensive analysis of human IL-4 receptor subunits shows compartmentalization in steady state and dupilumab treatment[J]. Allergy, 2023, 78(4): 1073-1087.
[19]	Spekhorst LS, van der Rijst LP, de Graaf M, et al. Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients[J]. Allergy, 2023, 78(3): 875-878.
[20]	金海杰, 益西拉姆, 王小牧, 等. 2型炎症性疾病抗体免疫疗法研究进展[J]. 药物生物技术, 2025, 32(3): 396-404.
	Jin HJ, Yi X, Wang XM, et al. Research progress on antibody immunotherapy for type 2 inflammatory disease[J]. Chin J Pharm Biotechnol, 2025, 32(3): 396-404. (in Chinese)
[21]	Ridolo E, Pucciarini F, Nizi MC, et al. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab[J]. Hum Vaccin Immunother, 2020, 16(10): 2349-2356.
[22]	Ramírez-Jiménez F, Pavón-Romero GF, Velásquez-Rodríguez JM, et al. Biologic therapies for asthma and allergic disease: past, present, and future[J]. Pharmaceuticals (Basel), 2023, 16(2): 270.
[23]	Lombardi C, Berti A, Cottini M. The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions[J]. Curr Res Immunol, 2022, 3: 42-53.
[24]	Faria N, Costa MI, Fernandes AL, et al. Biologic therapies for severe asthma: current insights and future directions[J]. J Clin Med, 2025, 14(9): 3153.
[25]	Sun LH, Ye YT, Huang SK, et al. Effectiveness and safety of dupilumab in children with moderate-to-severe asthma in China: a retrospective real-world study[J]. Chin Med J, 2025, 138(8): 1003-1005.
[26]	Preu? SL, Bieber K, Vorobyev A, et al. Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: a propensity-matched cohort study[J]. J Eur Acad Dermatol Venereol, 2025, 39(9): 1576-1587.
[27]	王怡玮, 宋洋, 徐艳华, 等. 度普利尤单抗治疗哮喘合并特应性共病有效性和安全性回顾性分析[J]. 中华临床免疫和变态反应杂志, 2024, 18(5): 439-445.
	Wang YW, Song Y, Xu YH, et al. Retrospective analysis on efficacy and safety of Dupilumab for treatment of asthma with atopic comorbidities[J]. Chin J Allergy Clin Immunol, 2024, 18(5): 439-445. (in Chinese)
[28]	Crimi C, Nolasco S, Noto A, et al. Long-term clinical and sustained REMIssion in severe eosinophilic asthma treated with mepolizumab: the REMI-M study[J]. J Allergy Clin Immunol Pract, 2024, 12(12): 3315-3327.
[29]	Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial[J]. Lancet Respir Med, 2017, 5(5): 390-400.
[30]	Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis[J]. N Engl J Med, 2017, 376(20): 1921-1932.
[31]	Braddock M, Hanania NA, Sharafkhaneh A, et al. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review[J]. Drug Saf, 2018, 41(5): 489-509.
[32]	Jacquel L, Hoellinger B, Marzolf G, et al. Atypical alveolar echinococcosis with systemic involvement in a patient treated with Dupilumab[J]. Rev Med Interne, 2024, 45(6): 382-386.
[33]	Krakowski AC, Senft SC, Heymann WR. Demodex folliculitis and recent dupilumab administration[J]. Pediatrics, 2021, 147(5): e2020029520.
[34]	Rodriguez-Lago L, Borrego L. Norwegian scabies in an atopic patient under Dupilumab treatment[J]. Dermatitis, 2022, 33(5): e54-e55.
[35]	Konstantinou GN, Podder I. Paradoxical worsening of chronic spontaneous urticaria following omalizumab administration: the missing link[J]. Cureus, 2024, 16(5): e61453.
[36]	Pera V, Brusselle GG, Riemann S, et al. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)[J]. Front Pharmacol, 2023, 14: 1276340.
[37]	Lifar P, Montastruc F, Reber LL, et al. Parasitic infections and biological therapies targeting type 2 inflammation: a VigiBase study[J]. Am J Respir Crit Care Med, 2023, 207(9): 1253-1255.
[38]	Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection[J]. Clin Exp Allergy, 2007, 37(2): 197-207.
[39]	Yalcin AD, Bisgin A, Cetinkaya R, et al. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma[J]. Clin Lab, 2013, 59(1/2): 71-77.
[40]	Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma[J]. N Engl J Med, 2021, 385(24): 2230-2240.
[41]	Rodrigo-Mu?oz JM, Gil-Martínez M, Sastre B, et al. Emerging evidence for pleiotropism of eosinophils[J]. Int J Mol Sci, 2021, 22(13): 7075.
[42]	Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with Mepolizumab[J]. N Engl J Med, 2008, 358(12): 1215-1228.
[43]	Edmonds N, Zhao P, Flowers RH. The use of Dupilumab in patients with HIV[J]. Int J STD AIDS, 2022, 33(14): 1165-1173.
[44]	Chow TG, Franzblau LE, Khan DA. Adverse reactions to biologic medications used in allergy and immunology diseases[J]. Curr Allergy Asthma Rep, 2022, 22(12): 195-207.
[45]	Omiunu A, Brown L, Kayastha D, et al. A rare case of disseminated amebiasis in a patient on biologic therapy for chronic rhinosinusitis[J]. Int Forum Allergy Rhinol, 2025, 15(1): 86-88.
[46]	Cai SR, Xu SL, Zhao Y, et al. Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: A meta-analysis of real-world evidence[J]. Allergy, 2025, 80(5): 1256-1270.

生物制剂	报告病例数	构成比/%	报告比值比OR	95%置信区间
度普利尤单抗	34	43.0	4.0	2.8~5.6
美泊利珠单抗	12	15.2	5.9	3.4~10.4
贝那利珠单抗	9	11.4	15.7	8.4~29.3
奥马珠单抗	24	30.4	3.9	2.6~5.8
总计	79	100

生物制剂	报告病例数	调整后比值比	95%置信区间
度普利尤单抗	15	1.50	0.53~5.32
美泊利珠单抗	5	3.68	0.97~5.32
贝那利珠单抗	9	9.49	3.08~35.07
奥马珠单抗	11	2.35	0.78~8.61
总计	40